REHOVOT, Israel and BRIDGEWATER, New Jersey, Nov. 3, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will provide a corporate overview at the 25 th Annual Credit Suisse Healthcare Conference, being held at the Phoenician Hotel in Scottsdale, Arizona, November 7-8, 2016.
25 th Annual Credit Suisse Healthcare Conference Presentation DetailsDate: Monday, November 7Time: 1:30pm Mountain Time/ 3:30pm Eastern TimeLocation: Ballroom DWebcast: https://cc.talkpoint.com/cred001/110716a_as/?entity=72_78NUEMHAbout Foamix Pharmaceuticals Ltd. Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological conditions. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of moderate-to-severe rosacea, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs. In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Mylan. For more information, please visit www.foamixpharma.com.